Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘Overcoming Resistance & Immunosuppression in Solid Tumors’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Thursday, April 20th at 3:00 p.m. ET.
Related news for (SNSE)
- Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
- Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
- Breaking News: MoBot’s Latest Update as of 03/28/25 10:00 AM
- Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
- Today’s Top Performers: MoBot’s Market Review 03/28/25 09:00 AM